

Special Issue

Measles, Mumps, and Rubella

Message from the Guest Editor

Vaccination against measles, mumps, and rubella has significantly reduced these infectious diseases' incidence, mortality, and morbidity. Efforts by countries and other organizations aim to eradicate these diseases. High-quality surveillance is crucial to confirm endemic transmission and control interruption in endemic areas. While global elimination of mumps is not the primary focus, countries with high vaccine uptake have notably reduced cases. Recent mumps outbreaks among vaccinated young adults suggest vaccine immunity waning.

Genotyping and sequence analysis are vital for defining the epidemiology of these diseases and documenting transmission interruption. More precise genotyping tools like extensive sequence analysis, whole genome sequencing, and bioinformatics are needed to track transmission as we near elimination.

This Special Issue aims to collate papers that explore molecular approaches used in the global surveillance and epidemiology of measles, mumps and rubella, with varied methodologies to characterise outbreaks and define the transmission of these vaccine-preventable viruses.

Guest Editor

Joanne Hiebert
Assistant

Guest Editor

Dr. Alberto Severini
Department of Medical Microbiology, Faculty of Health Sciences,
University of Manitoba, Winnipeg, MB R3E 0W2, Canada

Deadline for manuscript submissions

closed (31 May 2025)



Viruses

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/185939

Viruses
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

[mdpi.com/journal/
viruses](https://mdpi.com/journal/viruses)





Viruses

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
viruses](https://mdpi.com/journal/viruses)



About the Journal

Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Viruses* (ISSN 1999-4915). *Viruses* is published in open access format—research articles, reviews and other content are released on the internet immediately after acceptance. The scientific community and the general public have unlimited free access to the content as soon as it is published. As an open access journal, *Viruses* is supported by the authors or their institutes by payment of article processing charges (APC) for accepted papers. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Dr. Eric O. Freed

HIV Dynamics and Replication Program, Center for Cancer Research,
National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.2 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the second half of 2025).